TRVI Stock Analysis: Trevi Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.546m USD | 12M Return: 227.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 33.6M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 7.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for chronic cough, specifically targeting patients with idiopathic pulmonary fibrosis (IPF), non-IPF interstitial lung disease, and refractory chronic cough. The companys lead investigational product, Haduvio, is an oral extended-release formulation of nalbuphine, currently undergoing a Phase 2b clinical trial for chronic cough in IPF patients and a Phase 2a trial for refractory chronic cough.
The company operates in the Health Care sector (Pharmaceuticals sub-industry) under the GICS classification. As a clinical-stage biopharmaceutical firm, Trevi has no approved commercial products and is dependent on capital markets, licensing agreements, and eventual commercialization to generate revenue. Trevi holds a license agreement with Keenova Therapeutics plc covering nalbuphine hydrochloride formulations, and was incorporated in 2011, headquartered in New Haven, Connecticut. The company trades on NASDAQ under the ticker TRVI.
- Haduvio Phase 2b IPF chronic cough trial data readout
- FDA regulatory progress for Haduvio chronic cough indication
- Cash runway extends through key Haduvio trial milestones
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.18 > 0.02 and ΔFCF/TA 20.82 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -45.3m > Net Income -45.6m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 24.75 > 1.5 & < 3 |
| Outstanding Shares: last quarter (145.6m) vs 12m ago 23.79% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.14%; Δ -0.14% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.94 (Total Current Assets 176.1m - Total Current Liabilities 7.12m) / Total Assets 179.6m |
| B: -1.91 (Retained Earnings -343.0m / Total Assets 179.6m) |
| C: -0.32 (EBIT TTM -45.7m / Avg Total Assets 143.3m) |
| D: 23.01 (Book Value of Equity 172.1m / Total Liabilities 7.48m) |
| Altman-Z'' = 21.97 = AAA |
As of July 08, 2026, the stock is trading at USD 19.50 with a total of 5,525,809 shares traded. Over the past week, the price has changed by +4.67%, over one month by +44.44%, over three months by +48.85% and over the past year by +227.73%.
Current recommended Stop Loss: 18.40 (which is 5.6% or 1.3 ATR below the current price).
Trevi Therapeutics has received a consensus analysts rating of 4.88. Therefore, it is recommended to buy TRVI.
- StrongBuy: 7
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 23.9 | 22.6% |
P/B = 14.5174
Revenue TTM = 0.0 USD
EBIT TTM = -45.7m USD
EBITDA TTM = -45.5m USD
Long Term Debt = 364k USD (estimated: total debt 682k - short term 318k)
Short Term Debt = 318k USD (from shortTermDebt, last quarter)
Debt = 682k USD (from shortLongTermDebtTotal, last quarter) (leases 682k already included)
Net Debt = -171.1m USD (calculated: Debt 682k - CCE 171.8m)
Enterprise Value = 2.37b USD (2.55b + Debt 682k - CCE 171.8m)
Interest Coverage Ratio = unknown (Ebit TTM -45.7m / Interest Expense TTM 0.0)
EV/FCF = -74.35x (Enterprise Value 2.37b / FCF TTM -31.9m)
FCF Yield = -1.34% (FCF TTM -31.9m / Enterprise Value 2.37b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 132k) / Revenue TTM)
Tobins Q-Ratio = 13.22 (Enterprise Value 2.37b / Total Assets 179.6m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 682k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -36.1m (EBIT -45.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 24.75 (Total Current Assets 176.1m / Total Current Liabilities 7.12m)
Debt / Equity = 0.00 (Debt 682k / totalStockholderEquity, last quarter 172.1m)
Debt / EBITDA = 3.76 (negative EBITDA) (Net Debt -171.1m / EBITDA -45.5m)
Debt / FCF = 5.36 (negative FCF - burning cash) (Net Debt -171.1m / FCF TTM -31.9m)
Total Stockholder Equity = 185.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.83% (Net Income -45.6m / Total Assets 179.6m)
RoE = -24.53% (Net Income TTM -45.6m / Total Stockholder Equity 185.9m)
RoCE = -24.52% (EBIT -45.7m / Capital Employed (Equity 185.9m + L.T.Debt 364k))
RoIC = -20.88% (negative operating profit) (NOPAT -36.1m / Invested Capital 172.8m)
WACC = 6.19% (E(2.55b)/V(2.55b) * Re(6.19%) + D(682k)/V(2.55b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 6.19% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 98.88 | Cagr: 18.44%
[DCF] Fair Price = unknown (Cash Flow -31.9m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.90 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.11 | Chg30d=-10.00% | Revisions=+17% | Analysts=9
EPS next Quarter (2026-09-30): EPS=-0.13 | Chg30d=-8.32% | Revisions=+29% | Analysts=9
EPS current Year (2026-12-31): EPS=-0.47 | Chg30d=-9.81% | Revisions=+29% | GrowthEPS=-46.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.56 | Chg30d=+1.27% | Revisions=+50% | GrowthEPS=-19.0% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +47% (up=11, down=3)